Introduction
============

Distant metastasis remains the most commonly failure pattern for patients with nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT) and N classification has been reported to be the most crucial predictor for distant metastasis \[[@b1-crt-2018-595]-[@b4-crt-2018-595]\]. Magnetic resonance imaging (MRI) is recommended as the preferred modalities for the clinical staging of NPC \[[@b5-crt-2018-595]\]. However, radiomics features associated with MRI are not included in the N classification by the 8th edition of the American Joint Committee on Cancer (AJCC) system for NPC \[[@b6-crt-2018-595],[@b7-crt-2018-595]\].

Lymph nodal necrosis (LNN) is one of the most important imaging features used to distinguish between benign and malignant lymph nodes. At MRI, LNN is seen as a focal area of high signal intensity on T2-weighted images and as an area of low signal intensity on contrast material--enhanced T1-weighted images, with or without a surrounding rim of enhancement \[[@b8-crt-2018-595]\]. The incidence of LNN in NPC ranges from 22.9% to 44% \[[@b8-crt-2018-595]-[@b11-crt-2018-595]\]. A recent study conducted by Zhang et al. \[[@b11-crt-2018-595]\] demonstrated that LNN diagnosed on MRI was a negative prognostic factor for NPC after IMRI. Thus, in this study, we evaluated the prognostic value of MRI-determined LNN in NPC patients treated by IMRT and further explored the feasibility of an N-classification system based on the 8th edition of the AJCC system.

Materials and Methods
=====================

1. Patients and work-up
-----------------------

The medical records of consecutive 616 patients with previously untreated, biopsy-proven NPC with regional lymph nodes metastasis and no distant metastasis who were treated by IMRT between January 2007 and February 2012 in our center were retrospectively evaluated. The male (n=418)-to-female (n=198) ratio was 2.1:1, and the median age was 48 years (range, 14 to 81 years). Pathologically, non-keratinizing and keratinizing disease accounted for 99.4% (612 of 616) and 0.6% (4 of 616) of patients, respectively. All patients were restaged according to the 8th edition of the AJCC staging system. Classification T1, T2, T3, and T4 disease accounted for 15.1% (93 of 616), 15.1% (93 of 616), 38.6% (238 of 616), and 31.2% (192 of 616) of patients, respectively, and classification N1, N2, and N3 disease accounted for 49.4% (304 of 616), 34.4% (212 of 616), and 16.2% (100 of 616) of patients, respectively. The pretreatment workup included a complete history and physical examination, hematology, and biochemistry profiles, fiber-optic nasopharyngoscopy, MRI of the head and neck, bone scintigraphy, computed tomography scan of the chest and abdominal region, and dental check.

2. MR imaging
-------------

All patients underwent MRI on a 1.5- or 3.0-T system system (Magnetom Symphony/Verio, Siemens Healthcare, Erlangen, Germany) with a head and neck combined coil \[[@b12-crt-2018-595]\]. The scan range covered from the suprasellar cistern to the inferior margin of the sternoclavicular joint. Non-enhanced series included: axial T1-weighted imaging (T1WI), axial T2-weighted imaging, sagittal T1WI. Contrast-enhanced scan was performed after injection of gadopentetate dimeglumine with a dose of 0.2 mL/kg and rate of 2.0 mL/sec. Two radiologists with more than 10 years of experience in MRI of head and neck cancers independently evaluated all scans, and any disagreements were resolved by consensus. Also, there is a multidisciplinary team of head and neck cancers in our center to confirm the extent of diseases and the treatment of patients with NPC.

According to the previous study, diagnostic criteria for metastatic lymphadenopathy include (1) lateral retropharyngeal lymph node with a minimal axial diameter (MID) in the largest plane of an individual node at least 5 mm and any node seen in the median retropharyngeal group, lymph nodes with a MID of at least 11 mm in the jugulodigastric region and 10 mm for all other cervical nodes, excluding the retropharyngeal group; (2) lymph nodes of any size with central necrosis or a contrast-enhancing rim; (3) the presence of three or more contiguous and confluent lymph nodes, each of which should have a MID of 8 mm or more; and (4) lymph nodes of any size with extracapsular spread, including the presence of indistinct nodal margins, irregular nodal capsular enhancement or infiltration into the adjacent fat or muscle \[[@b13-crt-2018-595]\]. The criteria for diagnosing LNN at MRI are a focal area of high signal intensity on T2-weighted images or a focal area of low signal intensity on contrast-enhanced T1-weighted images, with or without a surrounding rim of enhancement \[[@b8-crt-2018-595]\].

3. Treatment
------------

All patients received definitive radiotherapy using IMRT techniques. A detailed description of IMRT has been previously reported \[[@b14-crt-2018-595]\]. Briefly, the dose prescribed was 69-70.4 Gy, 63-67.2 Gy, 60-60.8 Gy, and 54-54.4 Gy in 30-32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV) of primary tumor, PTV of metastatic lymph nodes, PTV of high-risk clinical target volume, and PTV of low-risk clinical target volume, respectively, using the simultaneous integrated boost technique. According to the institutional guidelines, concurrent chemotherapy was given for patients with stage II disease, and both neoadjuvant or adjuvant chemotherapy and concurrent chemotherapy were given for patients with locally advanced diseases. Neoadjuvant or adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil or cisplatin with docetaxel and 5-fluorouracil every 3 weeks for three cycles. Concurrent chemotherapy consisted of cisplatin 80 mg/m^2^ given on days 1 and 22 of radiotherapy. Deviations from the chemotherapy guidelines were allowed for patients aged over 70-year-old and/or patients with organ dysfunction suggesting intolerance to chemotherapy. Most patients (n=601, 97.5%) underwent platinum-based neoadjuvant, concurrent, or adjuvant chemotherapy.

4. Follow-up and statistical analysis
-------------------------------------

Follow-up was calculated from the day of radiation therapy completion to the date of the event or the last follow-up visit. All patients were followed up after the completion of radiotherapy: 1 month after the completion of radiotherapy, every 3 months in the first 2 years, every 6 months from year 3 to year 5, and annually thereafter.

The SPSS ver. 17.0 (SPSS Inc., Chicago, IL), software was used for statistical analysis. The locoregional failure free survival (LRFFS), distant metastasis free survival (DMFS), and overall survival (OS) were estimated by use of the Kaplan-Meier method. LRFFS, DMFS, and OS were measured from day 1 of treatment to the date of the event. Subgroup analysis of the LNN and non-LNN groups was conducted according to the T classification, N classification, and overall stage. Multivariate analyses with the Cox proportional hazards model were used to test independent significance by using backward elimination of insignificant explanatory variables. Host factors (age and sex) were included as the covariates in all tests. Also, the effect of N classification on risk for death and distant metastasis were performed by using the Cox proportional hazards model. All statistical tests were two sided, and p \< 0.05 was considered to be statistically significant.

5. Ethical statement
--------------------

This study was approved by the Institutional Review Board of Zhejiang Cancer Hospital with a waiver of informed consent and performed in accordance with the principles of the Declaration of Helsinki.

Results
=======

1. Incidence and size of LNN
----------------------------

In patients with positive lymph node metastases, the incidence of LNN was 38.1% (235 of 616) ([Fig. 1](#f1-crt-2018-595){ref-type="fig"}). Of 235 patients with LNN, 21.3% (50/235) had retropharyngeal lymph node involvement alone, 44.7% (105/235) had cervical lymph node involvement alone, whereas 34.0% (80 of 235) had both retropharyngeal and cervical lymph node involvement. Of 130 patients with retropharyngeal LNN, 83.1% (108/130) had unilateral retropharyngeal lymph node involvement, whereas 16.9% (22 of 130) had bilateral involvement. Of 185 patients with cervical LNN, 80.0% (148/185) had unilateral cervical lymph node involvement, whereas 20.0% (37 of 185) had bilateral involvement. The median maximal axial diameter of cervical positive lymph node was 24 mm (range, 0 to 89 mm) for all patients, 28 mm (range, 0 to 89 mm) for patients with LNN, and 20 mm (range, 0 to 71 mm) for patients without LNN (0 mm indicated patients with retropharyngeal lymph node involvement alone). The difference between the LNN and non-LNN groups in terms of the median maximal axial diameter of cervical positive lymph node was statistically significant (p \< 0.001). The T and N classification distribution according to lymph node status is shown in [Table 1](#t1-crt-2018-595){ref-type="table"}.

2. Treatment outcomes and subgroup analysis
-------------------------------------------

The median follow-up time was 62.6 months (range, 3.4 to 119.4 months); 43 of 616 patients (7.0%) were lost to follow-up. By the last follow-up, 22.1% (136/616) of patients developed treatment failure and more patients developed treatment failure in the LNN group (30.2% vs. 17.1%, p=0.001). The details of treatment failure are listed in [Table 2](#t2-crt-2018-595){ref-type="table"}. For all patients, the estimated 5-year LRFFS, DMFS, and OS rates were 87.5%, 86.7%, and 89.2%, respectively, and for the LNN and non-LNN groups, they were 78.8% vs. 91.8%, 78.2% vs. 91.2%, and 78.4% vs. 91.6% (p \< 0.05), respectively ([Fig. 2](#f2-crt-2018-595){ref-type="fig"}).

Subgroup analysis of lymph node status according to T classification, N classification, and overall stage are presented in [Table 3](#t3-crt-2018-595){ref-type="table"}. The estimated 5-year LRFFS and OS rates for patients with classification N2 disease and LNN were substantially poorer than patients with classification N2 disease without LNN (p \< 0.05). The estimated 5-year LRFFS, DMFS, and OS rates for patients with classification N2 disease and LNN were similar to patients with classification N3 disease (5-year LRFFS: 78.1% vs. 84.8%, p=0.112; DMFS: 81.0% vs. 77.5%, p=0.390; OS: 78.1% vs. 84.4%, p=0.367). Although the presence of LNN did not affect the survival outcomes for patients with classification N1 disease (p \> 0.05), those with classification N1 disease and LNN had similar survival outcomes as those with stage N2 disease without LNN, with estimated 5-year LRFFS, DMFS, and OS rates of 88.0% vs. 88.1% (p=0.899), 88.9% vs. 87.8% (p=0.942), and 87.9% vs. 94.4% (p=0.070), respectively.

3. Univariate and multivariate analyses
---------------------------------------

The value of various potential prognostic factors including age, sex, lymph node status, maximal axial diameter, T classification, N classification, and overall stage on predicting LRFFS, DMFS, and OS were evaluated. Univariate analysis by log-rank test showed that lymph node status (LNN vs. non-LNN) was associated with LRFFS, DMFS, and OS ([Table 4](#t4-crt-2018-595){ref-type="table"}). Multivariate analysis by Cox proportional-hazards model showed that the lymph node status (LNN vs. non-LNN), T classification, and N classification were independent prognostic predictors of DMFS. Age, lymph node status (LNN vs. non-LNN), and overall stage were independent prognostic predictors of OS ([Table 5](#t5-crt-2018-595){ref-type="table"}).

4. Proposed N classification system
-----------------------------------

Our data therefore suggested that N classification system could be optimized by adopting the following criteria: reclassified patients of classification N1 disease with LNN as classification N2, and classification N2 disease with LNN as classification N3. Correlation with death and distant failure was significant, and the total difference between N1 and N3 was wider with the proposed system. ([Table 6](#t6-crt-2018-595){ref-type="table"}). Furthermore, we used the area under the receiver operator characteristic curve (AUC) to quantify the prognostic performance of the proposed N classification system and the 8th edition of the N classification system. The AUC of the 8th edition of the N classification system was 0.551 (95% confidence interval \[CI\], 0.473 to 0.629) for death and 0.621 (95% CI, 0.554 to 0.689) for distant failure. The AUC of the proposed N classification system was higher than the 8th edition of the N classification system (0.606 \[95% CI, 0.530 to 0.683\] for death and 0.633 \[95% CI, 0.567 to 0.698\] for distant failure).

By the proposed system, 34.1% (210 of 616) of the patients were classified as N1, with 35.4% (218 of 616) as N2, and 30.5% (188 of 616) as N3. By the 8th AJCC system, 34.4% (212 of 616) would be classified as N2, and 16.2% (100 of 616) as N3, with the largest portion of patients (49.4%) as N1. We could conclude that the proposed system is obviously less skewed than that of the 8th AJCC system.

Discussion
==========

In this study, we observed a high incidence of LNN in NPC with lymph nodes metastasis and LNN is an independent prognostic factor of DMFS and OS in NPC after IMRT. The proposed N classification system of NPC including LNN based on MRI was more predictive than that of the 8th AJCC system.

The reported incidence of LNN in NPC ranges from 22.9% to 44% \[[@b8-crt-2018-595]-[@b11-crt-2018-595]\]. In the era of MRI, Mao et al. \[[@b9-crt-2018-595]\] reported that the incidence of LNN was only 26.5% of 786 NPC patients with positive cervical lymph nodes. However, when the retropharyngeal lymph node status was included, the reported incidence of LNN ranges from 33% to 44% \[[@b8-crt-2018-595],[@b11-crt-2018-595]\], which was similar to our results (38.1%).

The important implication of LNN is the presence of hypoxic tumor cells at the interface between necrotic areas and well-aerated cells. Increase in radioresistance of hypoxic tumor cells has been well documented. Also, tumor hypoxia may induce gene amplification associated with drug resistance \[[@b10-crt-2018-595]\]. IMRT has been accepted as the standard treatment technique of NPC \[[@b15-crt-2018-595]\]. In 2014, Tang et al. \[[@b16-crt-2018-595]\] reported that retropharyngeal LNN had a negative effect on disease failure in NPC after IMRT. In another study of 1,423 NPC patients treated by IMRT, multivariate analyses revealed that LNN was an independent negative prognostic factor for OS, DMFS, regional relapse-free survival, local relapse-free survival, and disease-free survival \[[@b11-crt-2018-595]\]. In the present study, multivariate analyses revealed LNN as a significant negative prognostic factor for OS and DMFS. A marginal significant difference was observed in terms of lymph node necrosis for LRFFS (p=0.058).

Four criteria were defined for a good staging classification system: (1) the different survival rates among the groups; (2) the given group including the subgroups defined by T, N, and M within a grouping system has similar survival rates; (3) the balanced distribution of patients among the groups; and (4) the high prediction of cure \[[@b17-crt-2018-595]\]. In the previous study, the total difference between classification N2 and N3 was wider with the proposed system which reclassified classification N1 with LNN as classification N2 and classification N2 with LNN as classification N3, and the hazard ratio discrimination between classification N2 and N3 was improved. Although a large cohort of patients (n=1,800) were included, most patients (n=1,064, 59.1%) were treated with conventional techniques and the AJCC 2010 staging system was adopted \[[@b8-crt-2018-595]\]. The proposed N classification system was proved to be powerfully predictive based on data with full statistical justification in the present study. More importantly, it meets the development of radiotherapy techniques and introduces the MRI-determined LNN to an N classification system for NPC based on the 8th AJCC system.

There are several limitations in the current study, including the retrospective nature of the study design and the inclusion of patients treated at a single center. We predict that patients with LNN may benefit from combined treatment. However, 97.5% patients underwent platinum-based chemotherapy, it would be inappropriate to evaluate the role of chemotherapy for patients with LNN in the present study. Moreover, multiparametric MRI-based radiomics from primary tumor provided improved prognostic ability in NPC \[[@b7-crt-2018-595]\]. The role of MRI-based radiomics from lymph nodes for NPC should be elucidated in the future.

In conclusion, MRI-determined LNN is an independent prognostic factor for NPC treated by IMRT. The proposed N classification system with MRI-determined LNN based on the 8th AJCC system is powerfully predictive.

Conflict of interest relevant to this article was not reported.

The present study was supported by Zhejiang Province Medical and Health Science and Technology Project (No. 2017182785, 2018-244679).

![Necrotic lymph nodes in two patients with nasopharyngeal carcinoma. Axial T2-weighted (A) and contrast-enhanced T1-weighted (B) magnetic resonance (MR) images in a 43-year-old woman show the left retropharyngeal lymph node with necrosis (arrows). Axial T2-weighted (C) and contrast-enhanced T1-weighted (D) MR images in a 40-year-old man show necrotic lymph nodes in the bilateral level II area (arrows).](crt-2018-595f1){#f1-crt-2018-595}

![Kaplan-Meier curves show locoregional failure-free survival (LRFFS) (A), distant metastasis-free survival (DMFS) (B), and overall survival (OS) (C) rates for the lymph nodal necrosis (LNN) and non-LNN groups. HR, hazard ratio; CI, confidence interval.](crt-2018-595f2){#f2-crt-2018-595}

###### 

Distribution of T and N classifications with lymph node status

       Non-LNN group (n=381)   LNN group (n=235)                                                                
  ---- ----------------------- ------------------- ----------- ------------ ----------- ----------- ----------- -----------
  T1   35 (57.4)               19 (31.1)           7 (11.5)    61 (16.0)    7 (21.9)    10 (31.3)   15 (46.9)   32 (13.6)
  T2   28 (49.1)               19 (33.3)           10 (17.5)   57 (15.0)    16 (44.4)   9 (25.0)    11 (30.6)   36 (15.3)
  T3   76 (51.4)               55 (37.2)           17 (11.5)   148 (38.8)   36 (40.0)   38 (42.2)   16 (17.8)   90 (38.3)
  T4   71 (61.7)               31 (27.0)           13 (11.3)   115 (30.2)   35 (45.5)   31 (40.3)   11 (14.3)   77 (32.8)

Values are presented as number (%). LNN, lymph nodal necrosis.

###### 

Patterns of treatment failure for all patients

  Treatment failure pattern          Non-LNN group (n=381)                                    LNN group (n=235)                                         p-value^[a)](#tfn1-crt-2018-595){ref-type="table-fn"}^
  ---------------------------------- -------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------
  **Distant only**                   25 (6.6)                                                 35 (14.9)                                                 0.001
   Bone                              7 (1.8)                                                  9 (3.8)                                                   
   Liver                             4 (1.0)                                                  12 (5.1)                                                  
   Lung                              11 (2.9)                                                 8 (3.4)                                                   
   Bone and liver                    2 (0.5)                                                  0                                                         
   Bone and lung                     0                                                        3 (1.3)                                                   
   Lung and liver                    0                                                        2 (0.9)                                                   
   Other                             1 (0.3)^[b)](#tfn2-crt-2018-595){ref-type="table-fn"}^   1 (0.4)^[c)](#tfn3-crt-2018-595){ref-type="table-fn"}^    
  **Regional and distant**           5 (1.3)                                                  5 (2.1)                                                   
  **Local and distant**              4 (1.0)                                                  1 (0.4)                                                   
  **Local, regional, and distant**   1 (0.3)                                                  2 (0.9)                                                   
  **Local only**                     15 (3.9)                                                 10 (4.3)                                                  
  **Regional only**                  9 (2.4)                                                  16 (6.8)^[d)](#tfn4-crt-2018-595){ref-type="table-fn"}^   
  **Local and regional**             6 (1.6)                                                  2 (0.9)                                                   
  **Total**                          65 (17.1)                                                71 (30.2)                                                 

Values are presented as number (%). LNN, lymph nodal necrosis.

p-values were calculated by using the chi-square test,

Left inguinal lymph nodes,

Include 1 failure in the left parotid region,

Lung, liver, mediastinal and retroperitoneal lymph nodes, and left adrenal gland.

###### 

Subgroup analysis of LNN and non-LNN groups between different clinical stage

                                 5-Year LRFFS   5-Year DMFS   5-Year OS                                       
  ------------------------------ -------------- ------------- ----------- ------ ------ ------- ------ ------ -------
  **T classification**                                                                                        
   T1                            95.8           73.5          0.008       96.6   90.6   0.021   98.2   93.5   0.273
   T2                            94.4           80.2          0.050       92.0   73.5   0.012   97.4   75.7   0.002
   T3                            85.8           90.1          0.553       89.9   84.3   0.156   91.9   87.6   0.456
   T4                            89.2           82.1          0.200       84.6   79.0   0.196   89.4   75.5   0.047
  **N classification**                                                                                        
   N1                            92.1           88.0          0.532       91.7   88.9   0.286   93.2   87.9   0.167
   N2                            88.1           78.1          0.023       87.8   81.0   0.127   94.4   78.1   0.001
   N3                            83.2           85.6          0.660       86.0   70.3   0.026   89.0   80.7   0.347
  **Overall stage (8th AJCC)**                                                                                
                                 100            85.4          0.089       94.7   91.1   0.475   98.2   88.8   0.109
                                 87.3           84.6          0.353       91.2   87.0   0.159   94.1   87.7   0.060
                                 88.1           82.9          0.351       86.1   76.1   0.012   89.5   77.1   0.032

Unless otherwise indicated, numbers are percentages. p-values were calculated by using the log-rank test. LNN, lymph nodal necrosis; LRFFS, locoregional failure free survival; DMFS, distant metastasis-free survival; OS, overall survival; AJCC, American Joint Committee on Cancer.

###### 

Univariate analysis of variables correlated with various clinical endpoints

  Characteristic                    No. of patients   5-Year LRFFS   p-value^[a)](#tfn5-crt-2018-595){ref-type="table-fn"}^   5-Year DMFS   p-value^[a)](#tfn5-crt-2018-595){ref-type="table-fn"}^   5-Year OS   p-value^[a)](#tfn5-crt-2018-595){ref-type="table-fn"}^
  --------------------------------- ----------------- -------------- -------------------------------------------------------- ------------- -------------------------------------------------------- ----------- --------------------------------------------------------
  **Sex**                                                                                                                                                                                                        
   Male                             418               86.3           0.201                                                    85.3          0.110                                                    88.3        0.304
   Female                           198               90.1                                                                    89.8                                                                   91.0        
  **Age (yr)**                                                                                                                                                                                                   
   ≥ 48                             319               87.6           0.815                                                    86.0          0.711                                                    85.8        0.017
   \< 48                            297               87.5                                                                    87.4                                                                   92.5        
  **Lymph node status**                                                                                                                                                                                          
   LNN                              235               83.8           0.049                                                    81.8          0.001                                                    82.9        \< 0.001
   Non-LNN                          381               89.7                                                                    89.8                                                                   93.0        
  **Maximal axial diameter (mm)**                                                                                                                                                                                
   ≥ 24                             310               85.5           0.061                                                    81.6          \< 0.001                                                 85.8        0.027
   \< 24                            306               89.6                                                                    91.8                                                                   92.6        
  **T classification**                                                                                                                                                                                           
   T1                               93                88.5           0.777                                                    94.5          0.071                                                    96.5        0.017
   T2                               93                89.2                                                                    84.8                                                                   88.9        
   T3                               238               87.4                                                                    87.8                                                                   90.3        
   T4                               192               86.5                                                                    82.4                                                                   83.9        
  **N classification**                                                                                                                                                                                           
   N1                               304               90.8           0.124                                                    90.9          \< 0.001                                                 91.5        0.248
   N2                               212               84.1                                                                    85.1                                                                   87.9        
   N3                               100               84.8                                                                    77.5                                                                   84.4        
  **Overall stage (8th AJCC)**                                                                                                                                                                                   
                                    86                96.1           0.111                                                    93.6          0.001                                                    95.8        0.002
                                    262               86.3                                                                    89.7                                                                   91.8        
                                    268               86.0                                                                    81.6                                                                   84.9        

LRFFS, locoregional failure free survival; DMFS, distant metastasis-free survival; OS, overall survival; LNN, lymph nodal necrosis; AJCC, American Joint Committee on Cancer.

p-values were calculated by using the log-rank test.

###### 

Multivariate analysis of variables correlated with various clinical endpoints

  Endpoint                    HR      95% CI         p-value
  --------------------------- ------- -------------- ---------
  **LRFFS**                                          
   Lymph node status                                 
    LNN vs. non-LNN           1.550   0.986-2.438    0.058
  **DMFS**                                           
   N classification                                  0.041
    N1                        1                      
    N2                        1.498   0.860-2.610    0.154
    N3                        2.288   1.204-4.346    0.011
   T classification                                  0.042
    T1                        1                      
    T2                        2.231   0.887-5.608    0.088
    T3                        1.708   0.736-3.965    0.212
    T4                        2.915   1.273-6.674    0.011
   Lymph node status                                 
    LNN vs. non-LNN           1.634   1.023-2.609    0.040
  **OS**                                             
   Age (yr)                                          
    ≥ 48 vs. \< 48            1.815   1.062-3.101    0.029
   Lymph node status                                 
    LNN vs. non-LNN           2.154   1.282-3.620    0.004
   Overall stage (8th AJCC)                          0.026
                              1                      
                              2.384   0.614-9.263    0.210
                              5.055   1.332-19.175   0.017

p-values were calculated by using the Cox proportional hazards model. HR, hazard ratio; CI, confidence interval; LRFFS, locoregional failure free survival; LNN, lymph nodal necrosis; DMFS, distant metastasis-free survival; OS, overall survival; AJCC, American Joint Committee on Cancer.

###### 

Effect of N classification for death and distant failure

                                          Death   Distant failure                                 
  --------------------------------------- ------- ----------------- ------- ------- ------------- ----------
  **Proposed system: N classification**                             0.004                         \< 0.001
   N1                                     1                                 1                     
   N2                                     1.149   0.566-2.331       0.700   1.562   0.819-2.978   0.175
   N3                                     2.549   1.346-4.824       0.004   3.240   1.786-5.878   \< 0.001
  **8th AJCC system: N classification**                             0.254                         \< 0.001
   N1                                     1                                 1                     
   N2                                     1.299   0.732-2.303       0.371   1.771   1.041-3.011   0.035
   N3                                     1.749   0.895-3.419       0.102   3.163   1.795-5.573   \< 0.001

Hazard ratios and p-values were calculated by using the Cox proportional hazards model. HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer.
